key: cord-0902200-u20v933i
authors: Atillasoy, Jem; Leasure, Audrey C.; Sheth, Kevin N.
title: Intracerebral Hemorrhage in COVID-19 Infection
date: 2021-08-20
journal: World Neurosurg
DOI: 10.1016/j.wneu.2021.06.102
sha: c4d710006c87f691505167b8bd8245f78aee2cfb
doc_id: 902200
cord_uid: u20v933i

nan

Jem Atillasoy, Audrey C. Leasure, Kevin N. Sheth

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic with over 174 million documented cases of COVID-19 infection. Typically, COVID-19 presents with respiratory disease; however, there have been numerous reports of neurologic manifestations including encephalopathy, seizure, and cerebrovascular disease. 1 Spontaneous intracerebral hemorrhage (ICH) has been reported as one of the most devastating manifestations of COVID-19. ICH is considered the most catastrophic stroke subtype with a >40% mortality rate and significant morbidity in survivors. 2 Roughly 40% of ICH deaths occur within the first month of the stroke, and it is approximated that only 20% of patients will make a full recovery. 2,3 Significant morbidity is associated with ICH, as hemorrhage-related injury may cause motor, memory, and language deficits. 3 Currently, the pathophysiology of ICH in COVID-19 is unknown, although there have been multiple proposed mechanisms. Potential mechanisms that may be involved include direct and indirect endothelial damage, ultimately promoting vessel rupture. 4 Directly, SARS-CoV-2 can invade endothelial cells through the ACE-2 receptor, resulting in cellular injury. Indirectly, endothelial toxicity can result systemically from a massive cytokine release, prothrombotic factors, and activation of the coagulation cascade, ultimately resulting in failure of the bloodbrain barrier. 4 Another potential theory is that a hypoxic state, as a result of respiratory disease, may predispose to endothelial dysfunction and potentially microscopic damage of cerebral veins. 5 In addition, there has been speculation about a disseminated intravascular coagulationÀtype reaction that would lead to a higher propensity for bleeding in the brain parenchyma. 5 An alternative explanation involves the neuroinvasive potential of the coronavirus family. Specifically, the SARS-CoV-2 virus can bind on neuronal and glial ACE-2 receptors, hence a pathway for direct intracranial invasion. 6 An extrinsic process could also contribute to ICH in COVID-19. Because COVID-19 patients are at an increased risk of thrombotic events, anticoagulation is often used and may play a causative role in the manifestation of ICH.

Given the severe sequelae of ICH and prevalence of COVID-19, several studies have assessed the clinical characteristics, treatments, and outcomes of ICH patients with COVID-19. Benger et al reported a series of cases characterizing ICH in patients with COVID-19. These patients were relatively young (mean age of 52.2) and had evidence of prolonged inflammation (elevated D-dimer) and ICH located in lobar territories. 4 Lawton et al 7 identified ICH patients from a single hospital who were COVID-19 positive and demonstrated that compared with a control group of COVID-19Ànegative ICH patients, the patients were younger, had worse outcomes, and longer lengths of stay in the hospital. Melmed et al 5 analyzed COVID-19 patients from the New York University Langone Health System and determined that older age, respiratory failure, ethnic minorities, and therapeutic anticoagulation were associated with ICH. Using a nationalclaims database, Ravindra et al 1 demonstrated that patients with ICH and COVID-19 infection had higher rates of in-hospital death and longer lengths of stay (in both the ICU and hospital) and were more likely to be a racial or ethnicity minority.

Studies have also examined the presence of ICH in COVID-19 hospitalized patients and their anticoagulation status. 5, 6, 8 Kvernland et al 6 reported an overall low rate of hemorrhage among COVID-19 patients with the majority of cases occurring in those who received therapeutic anticoagulation. Dogra et al 8 similarly reported that the majority of COVID-19 patients who developed ICH received anticoagulation therapy (either prophylactically or therapeutically) before ICH diagnosis. Moreover, Melmed et al 5 demonstrated that anticoagulation was associated with a 5Â increased risk of ICH. However, these studies were retrospective and observational and had a relatively small sample size.

A recent report from the American Heart Association COVID-19 Cardiovascular Disease registry examined the prevalence of ICH among hospitalized patients with COVID-19. 9 Similar to Kvernland et al, 6 this analysis suggests that ICH is rare among patients hospitalized for COVID-19. In addition, COVID-19Àpositive patients with ICH had more vascular risk factors and higher mortality compared with those without ICH. Similar to previous studies, this study reported a higher use of anticoagulation in ICH patients who are COVID-19 positive. 5, 6, 8 Although these analyses show that ICH may be a rare finding in COVID-19 patients, it is nevertheless important for clinicians to consider given the severe sequelae. Recognizing the difficulty in conducting a proper neurologic examination in heavily sedated patients, at minimum, pupillary reflex should be monitored in patients with COVID-19 requiring ICU-level care, especially for patients on anticoagulants. 10 We should note several limitations. First, the American Heart Association COVID-19 registry only included patients who were hospitalized with COVID-19, thus excluding those who were COVID-19 positive and did not seek hospital care. Also, the study lacked timing data, which prevented conclusions regarding the sequence of ICH, COVID-19 diagnosis, and anticoagulation therapy. Furthermore, this study lacked relevant neuroimaging data on the location and severity of ICH. Lastly, even though this was a multicentered study, the reporting hospitals may not adequately represent U.S. hospitals at large.

Myriad questions still need to be addressed in order to enhance our understanding of ICH and COVID-19. Determining the optimal role of anticoagulation in the treatment of COVID-19 will be essential as many hospitals use it for prophylaxis. Identifying risk factors and outcomes associated with ICH in patients with COVID-19, as well as describing the incidence of ICH during the COVID period compared with the pre-COVID period, will inform treatment approaches and development of clinical protocols. Characterizing ICH in patients with and without COVID-19 from a large, nationally representative registry will be important in confirming the aforementioned findings and proposed associations.

Furthermore, obtaining details regarding the timing of ICH relative to hospital admission, COVID-19 diagnosis, and anticoagulation will aid in establishing a potential causal effect of COVID-19 and ICH.

Impact of COVID-19 on the hospitalization, treatment, and outcomes of intracerebral and subarachnoid hemorrhage in the United States

Hemorrhagic stroke: intracerebral hemorrhage

Targeting TLR4-dependent inflammation in post-hemorrhagic brain injury

Intracerebral haemorrhage and COVID-19: clinical characteristics from a case series

Risk factors for intracerebral hemorrhage in patients with COVID-19

Anticoagulation use and hemorrhagic stroke in SARS-CoV-2 patients treated at a New York healthcare system

Coronavirus disease 2019 (COVID-19) can predispose young to intracerebral hemorrhage: a retrospective observational study

Hemorrhagic stroke and anticoagulation in COVID-19

Intracerebral hemorrhage in patients with COVID-19: an analysis from the COVID-19 cardiovascular disease registry

Catastrophic intracranial hemorrhage in two critically ill patients with COVID-19

is supported by the AHA Student Scholarship in Cerebrovascular Disease and Stroke and the Yale School of Medicine Medical Fellowship. A.C. Leasure is supported by the AHA Medical Student Research Fellowship. Dr

1878-8750/$ -see front matter ª